Goals: We reviewed our celiac disease (CeD) database to study if anti-tissue transglutaminase (tTG) antibody (ab) titers correlate with severity of villous abnormalities in Indian patients and to find out a cutoff value of anti-tTG ab fold-rise, which could best predict CeD.
C eliac disease (CeD) is an autoimmune disease, which occurs in genetically susceptible individuals and affects 1% of the world's population. 1 The diagnosis of CeD has been based classically on a triad of clinical manifestations, demonstration of villous abnormalities of various severity (assessed by histologic evaluation of the small intestinal mucosa), and unequivocal response to prolonged and continued avoidance of the dietary antigen. 2, 3 Advent of celiac-specific antibodies (a reflection of adaptive immune response to gluten peptide) has revolutionized the case detection rate and has led to recognition of CeD as a public health problem world over. In the present time celiac-specific serological tests including anti-tissue transglutaminase antibody (anti-tTG ab), anti-endomysial antibodies (AEA), and anti-deamidated gliadin peptide have become an integral part of not only screening and diagnosis but also for follow-up of patients with CeD. 1, 2 Recently, many studies on pediatric patients with CeD have suggested that high anti-tTG ab titers are almost 100% predictive of presence of villous atrophy on mucosal biopsies. [4] [5] [6] [7] [8] On the basis of these evidences, the recent guidelines by European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) have suggested that biopsies could be avoided in a small subset of patients who have very high titers of anti-tTG ab (>10 times upper limit of normal) in the presence of a positive anti-endomysial antibody and presence of susceptible HLA haplotype, that is, HLA-DQ2 and/or HLA-DQ8. 2 The data on positive predictive values (PPV) of high anti-tTG ab titers for diagnosing CeD in adult population is limited. [5] [6] [7] [8] [9] Furthermore, there is no data from tropical countries where there are many other causes of villous atrophy including tropical sprue, chronic giardiasis, protein energy malnutrition, and bacterial overgrowth. 10 Thus, in these countries, celiac-specific serological tests play even more pivotal role in the diagnosis of CeD.
CeD is emerging in Asia and prevalence of CeD has been found to be similar to western countries in many Asian countries including India and Iran. [11] [12] [13] As a large proportion of patients with CeD in these countries still remain undiagnosed, it will be interesting to see if similar correlation exists between anti-tTG ab titer and severity of villous abnormalities in Indian patients. Such data will help in making diagnosis of CeD much simpler in resourcelimited countries, where there is a large pool of patients with CeD and disproportionately limited availabilities of gastroenterologists, endoscopic facilities, and trained pathologists. We, therefore, reviewed our data of patients with CeD to study if anti-tTG ab titer correlate with severity of villous abnormalities and to find out a cutoff value of anti-tTG fold-rise, which best predicts presence of CeD.
PATIENTS AND METHODS
In this retrospective analysis, we reviewed the database of individuals tested anti-tTG ab-positive at our center. These individuals either presented with clinical manifestations of CeD to the outpatient clinic or were detected to be anti-tTG-positive during a population-based prevalence study. Individuals who had a positive anti-tTG ab and where biopsy blocks were available were included in this study. Any individual who was on gluten-restricted or gluten-free diet before serological and/or histologic tests were excluded from this study.
Over the period of time, the estimation of anti-tTG ab in our laboratory was carried out using >1 ELISA kits procured from different manufacturers: the Binding Site Limited (Birmingham, UK), Inova Diagnostics (San Diego, CA), and AESKU Diagnostics (Wendelsheim, Germany). tTG tests were carried out as per the manufacturer's instructions. Positive and negative controls were used. An anti-tTG titer of >4 U/mL for Binding Site, >20 U/mL for Inova diagnostics, and >18 U/mL for AESKU Diagnostics was considered as positive for CeD. In a few patients, the serological tests were conducted from commercially available laboratories. The cutoff values for a positive test varied between different diagnostic ELISA kits. To make uniformity, the titer of anti-tTG ab was also estimated again in a few patients if serum was stored with us. The results of anti-tTG ab titer were expressed as folds rise above the cutoff value (by calculating the ratio of observed anti-tTG ab titer divided by cutoff value for a positive test). Serum samples for serological testing were obtained within a month before obtaining intestinal biopsies. A few patients had undergone serological testing at 2 or multiple occasions but had not undergone mucosal biopsy testing. In such patients, only the most recent serology test (within 1 month) before the mucosal biopsy was considered. The gap between serology testing and obtaining of biopsies was <1 month in all the patients.
All these patients had undergone a standard diagnostic work-up as a standard of care at our center. All the patients had undergone evaluation for hematologic and biochemical parameters. All of them had undergone esophagogastroduodenoscopy and at least 4 to 6 biopsies had been obtained from the third part of the duodenum. A biopsy fragment was considered as oriented when at least 3 crypts were oriented perpendicularly on the underlying muscularis mucosae. Biopsies were analyzed for mucosal changes by 2 histopathologists with special interest in gastrointestinal pathology who were blinded to the clinical or serological results. The Modified Marsh grading system was used for grading mucosal changes: grade 0, normal histology (a crypt to villous ratio of 1:3 was taken as normal); grade 1: increase of intraepithelial lymphocytes (IEL) >40/100 enterocytes (IELs were identified as dark round cells with high nucleus to cytoplasmic ration, in comparison with the perpendicularly oriented cigar-shaped vesicular nuclei of the mucosal epithelial cells); grade 2: increased IELs along with crypt hyperplasia; and grade 3: increased IELs along with crypt hyperplasia and variable degrees of villous atrophy. 14 Only lymphocytic infiltrate at the tip of the villi (crescendo pattern) was taken in account. Crypt hyperplasia was identified as enlarged tortuous crypts with basophilic nuclei. A further semiquantitative subtyping of the villous atrophies was performed as follows: grade 3a/mild villous atrophy (duodenal biopsies with a crypt to villous ration of >1:3 but <1); grade 3b/moderate villous atrophy, C:V ratio of 1:1; grade 3c/severe villous atrophy, C:V ratio of >1. IELs were further subclassified empirically as follows: 1 + , IELs > 40 but r60/100 enterocytes; 2 + , IELs > 60 but r80/100 enterocytes; and 3 + , IELs > 80/100 enterocytes. The type and density of inflammatory infiltrate and extent of edema in lamina propria was recorded.
The diagnosis of CeD was made on the basis of the modified European Society of Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria, that is, clinical features, presence of villous atrophy (villous abnormalities of modified Marsh grade > 2), and unequivocal response to gluten-free diet. 2 Chronic diarrhea was defined as diarrhea persisting for >4 weeks. Anemia was diagnosed using WHO criteria for anemia, that is, (< 13 g/dL in male patients and <12 g/dL in female patients. 15 
Statistical Analysis
Analysis was carried out on STATA software, version 12.1. P-value of <0.05 was considered as significant. AntitTG ab fold-rise was expressed as mean ± SD and was compared between cases and control using the Student t test. Anti-tTG ab fold-rise was compared with various grades of villous atrophy using 1-way analysis of variance. ROC characteristics were determined to assess the discriminating ability of anti-tTG ab titer for presence or absence of villous atrophy. Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and positive predictive value for the presence of diagnosis of CeD was calculated based on the titer of anti-tTG ab. Similar analysis was conducted on CeD patients who presented with or without diarrhea and anemia.
RESULTS
A total of 366 anti-tTG ab-positive (169 male and 197 female patients) individuals were included in this study. The mean age (± SD) of the patients was 28.9 ± 12.4 years. The median duration of symptoms before the diagnosis of CeD was made was 36 months (interquartile range, 12 to 72 mo).
Mode of Presentation
The most common mode of presentation was chronic or recurrent diarrhea (147 patients, 40.2%), short stature (51, 13.9%), and refractory anemia (40, 10.9%). Sixty-eight patients (18.6%) were detected to have an anti-tTG ab during a general population prevalence study.
Grade of Villous Abnormalities
In this cohort, the maximum number of patients (137, 37.4%) had villous abnormalities of modified Marsh grade 3c. The villous abnormality of modified Marsh grade 0 was present in 63 (17.2%), grade 1 in 14 (3.8%), grade 2 in 33 (9.1%), grade 3a in 63 (17.2%), and grade 3b in 56 individuals (15.3%).
Correlation Between Titer of Anti-tTG ab and Severity of Villous Abnormalities
The mean anti-tTG ab fold-rise in group of patients with modified Marsh grader2 was 2.6 (± 2.5), grade 3a was 4 (± 3.9), grade 3b was 5.7 (± 5.2), and grade 3c was 11.8 (± 8.00) (Fig. 1) . The mean anti-tTG ab fold-rise in patients with CeD was 8.7 (± 7.6). The mean anti-tTg foldrise in group with grade 3c was significantly higher as compared with 3 other groups (P-value < 0.001 for each). Similarly, the mean tTG fold-rise in the group with grade 3b was significantly higher than those with grade r2 (P-value <0.001).
There was no effect of duration of symptoms of CeD on the correlation between anti-tTG ab titers and severity of villous abnormalities. However, patients having villous abnormalities of Marsh grade 3c had significantly higher anti-tTG fold-rise, both in patients with duration of symptoms >12 months (115 patients) and those with symptoms r12 months (51 patients).
Correlation between degree of villous damage and anti-tTG titer were analyzed separately for both adolescent (r18 y) as well as adult patients (>18 y). In both the groups, patients with severe villous abnormalities had significantly higher anti-tTG fold-rise as compared with those with villous abnormalities of modified Marsh grade 2, 3a, or 3b.
Assessment of a Positive Predictive Value for Anti-tTG Titer Fold-Rise
The PPV at various anti-tTG fold-rise levels for diagnosis of CeD has been shown in Table 1 . As expected, the PPV for diagnosing CeD increased with progressive increase in the anti-tTG titer fold-rise. The prediction of CeD, irrespective of symptoms, was 100% if anti-tTG titer was 14-fold higher than the cutoff titer for a positive test. Furthermore, 57 (43.8%) individuals having low-titerpositive (< 2-fold) anti-tTG ab also had CeD.
Likelihood Ratio for Diagnosis of CeD at Various Levels of Anti-tTG Titers
Positive likelihood ratio for diagnosing CeD increased with increase in anti-tTG fold-rise levels ( Table 2 ). The positive likelihood ratio for diagnosing CeD was 15.4 and 28.7 at 12-and 14-fold-rise of anti-tTG titers, respectively. As expected, specificity also increased with increase in antitTG fold-rise and reached 100% at cutoff of 14-fold-rise.
Combination of Clinical Symptoms and Anti-tTG Titer on Prediction of Severity of Villous Abnormalities and CeD

Effect of Chronic Diarrhea on PPV for Diagnosing CeD
The data on presence or absence of chronic diarrhea were available in 338 patients. The PPV for diagnosing CeD was 100% at the anti-tTG titer >12-fold if the patient had diarrhea (Table 3) , which was <14-fold-rise of anti-tTG required for 100% PPV for diagnosing CeD irrespective of symptoms. At each fold-rise of anti-tTG titer, the PPV for diagnosing CeD was higher for those who had diarrhea compared with those who did not have diarrhea.
Effect of Anemia on PPV for Diagnosing CeD
The data on hemoglobin was present in 313 patients. The PPV for diagnosing CeD was 100% at 14-fold-rise of anti-tTG titer in presence of anemia, which was same as anti-tTG fold-rise required for 100% PPV for diagnosing CeD in the overall study population. At each fold-rise of anti-tTG titer, the PPV for diagnosing CeD was higher for the anemia group when compared with group without anemia ( Table 4) .
Effect of Both Diarrhea and Anemia on PPV for Diagnosing CeD
A total of 147 patients had both diarrhea and anemia. The PPV for diagnosing CeD was 100% when the anti-tTG titer was Z8.5-fold above cutoff values, which was much lower than tTG fold-rise required for 100% PPV for diagnosing CeD in the other groups mentioned above.
Correlation Between Presence of Anemia With Degree of Villous Atrophy and Anti-tTG Titer
The mean hemoglobin in patients having villous abnormalities of Marsh grade 3a, grade 3b, and grade 3c were 11.8 ± 2.2, 10.5 ± 2.7, 10.4 ± 2.6, and 8.8 ± 2.3 g/dL, respectively. The mean hemoglobin in group with severe villous atrophy (Marsh grade 3C) was significantly lower than the other 3 groups (P-value < 0.001 for each). Similarly, patients with mild and moderate villous atrophy had significantly higher mean hemoglobin levels when compared with those with no villous atrophy (P-value 0.008 and 0.01, respectively). Similarly, as the anti-tTG titer fold-rise increased in these patients, the mean hemoglobin levels decreased (P-value <0.001 and r = À0.28) (Fig. 2) .
DISCUSSION
In the present study, we demonstrated that as titer of anti-tTG ab rises, the severity of villous abnormalities also increases. The PPV was 100% for presence of villous atrophy of modified Marsh grade 3 if anti-tTG ab titer was >14-fold. Furthermore, in presence of symptoms such as diarrhea or anemia, the PPV for presence of villous atrophy was 100%, even at lower level of anti-tTG ab titer (12-fold rise). If both diarrhea and anemia were present, the PPV for presence of villous atrophy was 100% when the anti-tTG ab titer was 8.5-fold above the cutoff value for a positive test. Therefore, in some patients who have such high antitTG titer, a presence of villous abnormality of Marsh grade 3 can be predicted and the diagnosis of CeD could be made confidently even without performing duodenal biopsies.
Several studies have suggested that the serological titers correlate well with degree of villous abnormalities. [4] [5] [6] [7] [8] [9] A multicentre study on 412 children by Alessio et al 8 has shown that an anti-tTG titer fold-rise of Z7 was able to identify all the children with significant mucosal damage (Marsh gradeZ2). Hill and Holmes 4 reported a PPV of 100% for diagnosing CeD at an anti-tTG ab fold-rise of 10-fold in adult patients with CeD. These studies and data from the present study suggest that high titers of anti-tTG ab could be used as a surrogate marker of presence of significant villous abnormalities and for the diagnosis of CeD.
Not only a correlation exists between the titer of antitTG ab and severity of villous abnormalities, but a correlation between villous abnormalities and gastrointestinal symptoms, laboratory parameters, and health-related quality of life has also been shown by Taavela et al. 16 A similar correlation was observed between anti-tTG ab titer and symptoms and laboratory parameters in the present study as well. 16 We also observed lower mean hemoglobin with increase in the titer of anti-tTG ab. Similar correlation between hemoglobin level and severity of villous damage has recently been described in Indian children with CeD. 10 CeD is evolving all over the world, including certain Asian countries. 17 The presence of villous abnormalities could be found in many other conditions such as tropical sprue, giardiasis, and small bowel bacterial overgrowth. 10, 18 Furthermore, there is an overlap between symptoms of tropical sprue and CeD, and it is extremely difficult to differentiate these 2 conditions based on clinical and histologic features. 19 CeD-specific serological tests are of great help in differentiating these 2 conditions.
There has been a long debate on whether biopsies can be avoided in making a diagnosis of CeD. In many countries where endoscopy is not frequently available at primary and secondary care center, the diagnosis of CeD is likely to be delayed. In such situation, one can still make a diagnosis of CeD if the titer of anti-tTG is very high. Furthermore, intestinal lesions may be patchy and intestinal biopsies sample only a minute fraction of the intestine and may not be representative of the true villous abnormalities in other segments of the intestine. It has been observed that a nearto-close linear relationship exists between rising level of antitTG ab and increasing severity of villous abnormities from Marsh grade 1 to Marsh grade 3C, that is, gradual changes from normal villous architecture to overt mucosal atrophy.
One should realize that a considerable amount of variability exists between the readings of commercially available ELISA kits supplied by different manufacturers. A high titer reported by one commercially available ELISA kit on a particular serum sample is reported having low titer by other ELISA kits (unpublished observation). It is therefore advisable to gather more evidences for presence of CeD rather than relying only on a single high titer of antitTG ab. That is what has been recommended by the ESPGHAN in their recent recommendations on the diagnosis of CeD. 2 Establishment of presence of villous abnormalities in the presence of a positive anti-tTG ab adds strength to the diagnosis. The intestinal lesions are at best nonspecific, and the philosophy of performing a biopsy is to In addition to anti-tTG ab and endomysial antibody, other serological tests such as anti-deamidated gliadin peptides antibody have recently been found to be equally sensitive and specific for diagnosing CeD. 20 However, many of these tests are immunoglobulin A (IgA)-based and IgA deficiency needs to be ruled out before interpreting these results. Furthermore, there are now efforts to find out a noninvasive marker of villous abnormalities. An inverse correlation has been observed between levels of plasma citrulline and grades of villous abnormalities in a few small uncontrolled studies. [21] [22] [23] In a recent study, Adriaanse et al 24 showed a correlation between level of intestinal fatty acid binding protein and severity of villous abnormalities. We recently have demonstrated a correlation between functional activity of CYP3A4 (C max of simvastatin) and presence of villous abnormalities. 25 Similarly, a preliminary study has reported utility of regenerating gene (REG) Ia serum levels as a potential biomarker for diagnosing and monitoring CeD. 26 Further studies on the potential biomarkers of villous abnormalities may add value in the diagnostic algorithm of CeD.
Another observation in this study was that the villous atrophy was present in 50% of patients even at relatively lower titer (2-fold) of anti-tTG ab. Therefore, CeD may be present in those having even lower titer of anti-tTG ab titer. Lower titer of anti-tTG ab has lower predictive value for presence of villous atrophy and thus duodenal biopsies should be performed in all such patients to demonstrate presence or absence of significant villous abnormalities.
What could be the biologic basis of the correlation between severity of villous abnormalities and the titer of anti-tTG ab? There are more opinions than the facts. Taking an analogy, a correlation has been found between antidsDNA antibody level and the disease activity of systemic lupus erythematosus. 27 Furthermore, anti-dsDNA ab has also been shown to be involved in the pathogenesis of systemic lupus erythematosus. 27 In fact, anti-tTG ab have been implicated in the pathogenesis of CeD. In vitro study using T84 crypt cell fibroblast coculture, Halttunen and Maki observed significant inhibition of T84 epithelial cell differentiation and increase in epithelial cell proliferation with addition of monoclonal antibodies against tTG. 28 The authors speculated that this effect was caused by the blockage of the activating action displayed by tTG on TGFb, 28 In fact, TGF-b is normally secreted in a latent form and needs to be activated for biological activity, and tTG is known to be involved in the activation of latent TGF-b. 28, 29 In the present study, a large number of patients (n = 110) having early villous changes (modified Marsh grade <3) were included, which is one of the merits.
In conclusion, as the severity of villous abnormality increases, the titer of anti-tTG ab also increases. Duodenal biopsy could be avoided in some individuals with very high anti-tTG ab titer (>14 times). In contrast to emerging belief, mucosal biopsies should be carried out even in those with anti-tTG titer <2-fold-rise.
